A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC

• Status: Terminated
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

A Long-term Follow-up Study for Cardiac Safety in the Patients with HER2 Positive Early or Locally Advanced Breast Cancer Who Have Completed the SB3-G31-BC

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samsung Bioepis Co., Ltd.
• Treatments: Trastuzumab

Criteria

Inclusion Criteria:

• Subjects who received the study treatment of SB3-G31-BC.

• Subjects who provide informed consent.

Exclusion Criteria:

• Subjects unwilling to follow the study requirements are not eligible for the study.